Apr 4, 2013
ESAs and a New Class of Late Stage Oral HIF-PH Inhibitors May Be...
BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, compared to just one year ago, the mean hemoglobin at erythropoiesis-stimulating agent initiation has significantly declined and is nearing levels at which a blood transfusion may be required.
Rockwell Poised For Post-Offering Bounce Ahead Of Phase III Results
Rockwell Medical is a fully integrated provider of products and services for patients with end-stage renal disease and chronic kidney disease that require dialysis.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
Treating Anemia in Older Adults With Heart Failure With a Preserved...
Correspondence to Mathew S. Maurer, MD, Clinical Cardiovascular Research Laboratory for the Elderly, Allen Hospital of NewYork Presbyterian, 5141 Broadway, 3 Field West Room 035, New York, NY 10034.
New FDA Warnings for Anemia Drugs
March 9, 2007 -- Federal regulators announced new warnings for anemia drugs Friday following evidence that they can worsen cancer and increase the risk of death in some patients.